Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Amortization of Deferred Charges (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Amortization of Deferred Charges for 15 consecutive years, with $676000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Amortization of Deferred Charges rose 13.23% year-over-year to $676000.0, compared with a TTM value of $2.6 million through Dec 2025, up 13.62%, and an annual FY2025 reading of $2.6 million, up 13.62% over the prior year.
  • Amortization of Deferred Charges was $676000.0 for Q4 2025 at Amicus Therapeutics, up from $658000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $721000.0 in Q3 2023 and bottomed at $531000.0 in Q1 2024.
  • Average Amortization of Deferred Charges over 5 years is $628600.0, with a median of $641500.0 recorded in 2021.
  • The sharpest move saw Amortization of Deferred Charges skyrocketed 140.26% in 2021, then fell 20.39% in 2024.
  • Year by year, Amortization of Deferred Charges stood at $638000.0 in 2021, then increased by 5.17% to $671000.0 in 2022, then dropped by 20.12% to $536000.0 in 2023, then rose by 11.38% to $597000.0 in 2024, then rose by 13.23% to $676000.0 in 2025.
  • Business Quant data shows Amortization of Deferred Charges for FOLD at $676000.0 in Q4 2025, $658000.0 in Q3 2025, and $630000.0 in Q2 2025.